Venous congestion and pulmonary vascular function in Fontan circulation: Implications for prognosis and treatment

Alexander Egbe, Yogesh N.V. Reddy, Arooj R. Khan, Mohamad Al-Otaibi, Emmanuel Akintoye, Masaru Obokata, Barry A Borlaug

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Elevation in central venous pressure (CVP) plays a fundamental pathophysiologic role in Fontan circulation. Because there is no sub-pulmonary ventricle in this system, CVP also provides the driving force for pulmonary blood flow. We hypothesized that this would make Fontan patients more susceptible to even low-level elevation in pulmonary vascular resistance index (PVRI), resulting in greater systemic venous congestion and adverse outcomes. Methods: Adult Fontan patients and controls without congenital heart disease undergoing clinical evaluation that included cardiac catheterization and echocardiography were examined retrospectively. Outcomes including all-cause mortality and the development of Fontan associated diseases (FAD, defined as protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, or thromboembolism) were assessed from longitudinal assessment. Results: As compared to controls (n = 82), Fontan patients (n = 164) were younger (36 vs 45 years, p < 0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a strong correlation between CVP and PVRI in the Fontan group (r = 0.79, p < 0.001), but there was no such relationship in controls. Elevated PVRI identified patients at increased risk for FAD (HR 1.92, 95% CI 1.39–2.41, p = 0.01), and composite endpoint of FAD and/or death (HR 1.89, 95% CI 1.32–2.53, p = 0.01) per 1 WU∗m2 increment. Conclusions: Systemic venous congestion, which is the primary factor in the pathogenesis of FAD and death, is related to even low-level abnormalities in pulmonary vascular function. Multicenter studies are needed to determine whether interventions targeting pulmonary vascular structure and function can improve outcomes in the Fontan population.

Original languageEnglish (US)
JournalInternational Journal of Cardiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Flavin-Adenine Dinucleotide
Hyperemia
Central Venous Pressure
Blood Vessels
Vascular Resistance
Lung
Cardiac Arrhythmias
Fibrosis
Protein-Losing Enteropathies
Thromboembolism
Therapeutics
Cardiac Catheterization
Multicenter Studies
Echocardiography
Heart Diseases
Hospitalization
Heart Failure
Mortality
Population

Keywords

  • Central venous pressure
  • Fontan associated diseases
  • Fontan failure
  • Pulmonary vascular resistance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Venous congestion and pulmonary vascular function in Fontan circulation : Implications for prognosis and treatment. / Egbe, Alexander; Reddy, Yogesh N.V.; Khan, Arooj R.; Al-Otaibi, Mohamad; Akintoye, Emmanuel; Obokata, Masaru; Borlaug, Barry A.

In: International Journal of Cardiology, 01.01.2018.

Research output: Contribution to journalArticle

@article{23908a1eacce408a886b3f37ae0e5ada,
title = "Venous congestion and pulmonary vascular function in Fontan circulation: Implications for prognosis and treatment",
abstract = "Background: Elevation in central venous pressure (CVP) plays a fundamental pathophysiologic role in Fontan circulation. Because there is no sub-pulmonary ventricle in this system, CVP also provides the driving force for pulmonary blood flow. We hypothesized that this would make Fontan patients more susceptible to even low-level elevation in pulmonary vascular resistance index (PVRI), resulting in greater systemic venous congestion and adverse outcomes. Methods: Adult Fontan patients and controls without congenital heart disease undergoing clinical evaluation that included cardiac catheterization and echocardiography were examined retrospectively. Outcomes including all-cause mortality and the development of Fontan associated diseases (FAD, defined as protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, or thromboembolism) were assessed from longitudinal assessment. Results: As compared to controls (n = 82), Fontan patients (n = 164) were younger (36 vs 45 years, p < 0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a strong correlation between CVP and PVRI in the Fontan group (r = 0.79, p < 0.001), but there was no such relationship in controls. Elevated PVRI identified patients at increased risk for FAD (HR 1.92, 95{\%} CI 1.39–2.41, p = 0.01), and composite endpoint of FAD and/or death (HR 1.89, 95{\%} CI 1.32–2.53, p = 0.01) per 1 WU∗m2 increment. Conclusions: Systemic venous congestion, which is the primary factor in the pathogenesis of FAD and death, is related to even low-level abnormalities in pulmonary vascular function. Multicenter studies are needed to determine whether interventions targeting pulmonary vascular structure and function can improve outcomes in the Fontan population.",
keywords = "Central venous pressure, Fontan associated diseases, Fontan failure, Pulmonary vascular resistance",
author = "Alexander Egbe and Reddy, {Yogesh N.V.} and Khan, {Arooj R.} and Mohamad Al-Otaibi and Emmanuel Akintoye and Masaru Obokata and Borlaug, {Barry A}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ijcard.2018.05.039",
language = "English (US)",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Venous congestion and pulmonary vascular function in Fontan circulation

T2 - Implications for prognosis and treatment

AU - Egbe, Alexander

AU - Reddy, Yogesh N.V.

AU - Khan, Arooj R.

AU - Al-Otaibi, Mohamad

AU - Akintoye, Emmanuel

AU - Obokata, Masaru

AU - Borlaug, Barry A

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Elevation in central venous pressure (CVP) plays a fundamental pathophysiologic role in Fontan circulation. Because there is no sub-pulmonary ventricle in this system, CVP also provides the driving force for pulmonary blood flow. We hypothesized that this would make Fontan patients more susceptible to even low-level elevation in pulmonary vascular resistance index (PVRI), resulting in greater systemic venous congestion and adverse outcomes. Methods: Adult Fontan patients and controls without congenital heart disease undergoing clinical evaluation that included cardiac catheterization and echocardiography were examined retrospectively. Outcomes including all-cause mortality and the development of Fontan associated diseases (FAD, defined as protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, or thromboembolism) were assessed from longitudinal assessment. Results: As compared to controls (n = 82), Fontan patients (n = 164) were younger (36 vs 45 years, p < 0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a strong correlation between CVP and PVRI in the Fontan group (r = 0.79, p < 0.001), but there was no such relationship in controls. Elevated PVRI identified patients at increased risk for FAD (HR 1.92, 95% CI 1.39–2.41, p = 0.01), and composite endpoint of FAD and/or death (HR 1.89, 95% CI 1.32–2.53, p = 0.01) per 1 WU∗m2 increment. Conclusions: Systemic venous congestion, which is the primary factor in the pathogenesis of FAD and death, is related to even low-level abnormalities in pulmonary vascular function. Multicenter studies are needed to determine whether interventions targeting pulmonary vascular structure and function can improve outcomes in the Fontan population.

AB - Background: Elevation in central venous pressure (CVP) plays a fundamental pathophysiologic role in Fontan circulation. Because there is no sub-pulmonary ventricle in this system, CVP also provides the driving force for pulmonary blood flow. We hypothesized that this would make Fontan patients more susceptible to even low-level elevation in pulmonary vascular resistance index (PVRI), resulting in greater systemic venous congestion and adverse outcomes. Methods: Adult Fontan patients and controls without congenital heart disease undergoing clinical evaluation that included cardiac catheterization and echocardiography were examined retrospectively. Outcomes including all-cause mortality and the development of Fontan associated diseases (FAD, defined as protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, or thromboembolism) were assessed from longitudinal assessment. Results: As compared to controls (n = 82), Fontan patients (n = 164) were younger (36 vs 45 years, p < 0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a strong correlation between CVP and PVRI in the Fontan group (r = 0.79, p < 0.001), but there was no such relationship in controls. Elevated PVRI identified patients at increased risk for FAD (HR 1.92, 95% CI 1.39–2.41, p = 0.01), and composite endpoint of FAD and/or death (HR 1.89, 95% CI 1.32–2.53, p = 0.01) per 1 WU∗m2 increment. Conclusions: Systemic venous congestion, which is the primary factor in the pathogenesis of FAD and death, is related to even low-level abnormalities in pulmonary vascular function. Multicenter studies are needed to determine whether interventions targeting pulmonary vascular structure and function can improve outcomes in the Fontan population.

KW - Central venous pressure

KW - Fontan associated diseases

KW - Fontan failure

KW - Pulmonary vascular resistance

UR - http://www.scopus.com/inward/record.url?scp=85047251698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047251698&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2018.05.039

DO - 10.1016/j.ijcard.2018.05.039

M3 - Article

C2 - 30223363

AN - SCOPUS:85047251698

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -